Clinical outcomes and adverse effect monitoring in allergic rhinitis

Slides:

Advertisements

Similar presentations

Clinical trial design, nasal allergen challenge models, and considerations of relevance to pediatrics, nasal polyposis, and different classes of medication

Advertisements

Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis Fuad M. Baroody, MD, David Brown, MD,

Allergen immunotherapy: A practice parameter third update

Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses Stephen R. Durham,

Treating acute rhinosinusitis: Comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo Eli O. Meltzer, MD, Claus Bachert,

David B Allen, MD Journal of Allergy and Clinical Immunology

Asthma exacerbations: Origin, effect, and prevention

Alalia Berry, MD, William W. Busse, MD

Clinical outcomes and adverse effect monitoring in allergic rhinitis

Safety and efficacy of mometasone furoate aqueous nasal spray in children with allergic rhinitis: Results of recent clinical trials Javier Dibildox,

A review of the preclinical and clinical data of newer intranasal steroids used in the treatment of allergic rhinitis William R. Lumry, MD Journal of.

Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses Stephen R. Durham,

Asthma diagnosis and treatment: Filling in the information gaps

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD

Ann-Marie M. Schoos, MD, PhD, Jacob D

Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis Harold B. Kaiser, MD, Robert M. Naclerio, MD,

Exposure of infants to budesonide through breast milk of asthmatic mothers Anette Fält, BSc, Thomas Bengtsson, MSc, Britt-Marie Kennedy, BSc, Ann Gyllenberg,

Eli O. Meltzer, MD, Michael S. Blaiss, MD, M

David A. Khan, MD Journal of Allergy and Clinical Immunology

Is 9 more than 2 also in allergic airway inflammation?

Probiotics during the first 7 years of life: A cumulative risk reduction of eczema in a randomized, placebo-controlled trial Marko Kalliomäki, MD, PhD,

Sublingual epinephrine tablets versus intramuscular injection of epinephrine: Dose equivalence for potential treatment of anaphylaxis Mutasem M. Rawas-Qalaji,

Bruce M. Prenner, MD, Bobby Q. Lanier, MD, David I

Safety and efficacy of mometasone furoate aqueous nasal spray in children with allergic rhinitis: Results of recent clinical trials Javier Dibildox,

Prenatal adverse life events increase the risk for atopic diseases in children, which is enhanced in the absence of a maternal atopic predisposition

Children with allergic and nonallergic rhinitis have a similar risk of asthma Bo Lund Krogsgaard Chawes, MD, Klaus Bønnelykke, MD, PhD, Eskil Kreiner-Møller,

Stanley J. Szefler, MD, Richard J. Martin, MD

Comparison of the efficacy of budesonide and fluticasone propionate aqueous nasal spray for once daily treatment of perennial allergic rhinitis James.

As-needed use of fluticasone propionate nasal spray reduces symptoms of seasonal allergic rhinitis Albert Jen, MD, Fuad Baroody, MD, Marcy de Tineo,

Keith J. Simons, PhD, Margherita Strolin Benedetti, PhD, F. Estelle R

Lieuwe D. Bos, MSc, PhD, Peter J. Sterk, MD, PhD, Stephen J

Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis Fuad M. Baroody, MD, David Brown, MD,

Peter M. Wolfgram, MD, David B. Allen, MD

Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations Raymond G.

Peter König, MD, PhD Journal of Allergy and Clinical Immunology

Intranasal triamcinolone use during pregnancy and the risk of adverse pregnancy outcomes Anick Bérard, MSc, PhD, Odile Sheehy, MSc, Marie-Laure Kurzinger,

Prescribing practices and asthma control with hydrofluoroalkane-beclomethasone and fluticasone: A real-world observational study David Price, FRCGP,

Gene Colice, MD, Richard J

Tolerated wasp sting challenge improves health-related quality of life in patients allergic to wasp venom Jörg Fischer, MD, Martin Teufel, MD, Alexandra.

What is an “eosinophilic phenotype” of asthma?

Medication use in children with asthma in Finland from 1995 to 2006

Clinical need for a nebulized corticosteroid

Immune responses to mosquito saliva in 14 individuals with acute systemic allergic reactions to mosquito bites Zhikang Peng, MD, Andrew N. Beckett, BSc,

Treating acute rhinosinusitis: Comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo Eli O. Meltzer, MD, Claus Bachert,

Autophagy: Nobel Prize 2016 and allergy and asthma research

Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment

Objective monitoring of nasal airway inflammation in rhinitis

The effects of antihistamines on cognition and performance

Therapeutic strategies to reduce asthma exacerbations

Anaphylaxis during anesthesia in France: An 8-year national survey

Piotr Kuna, MD, Jadwiga Kaczmarek, MD, Maciej Kupczyk, MD

Exposure of infants to budesonide through breast milk of asthmatic mothers Anette Fält, BSc, Thomas Bengtsson, MSc, Britt-Marie Kennedy, BSc, Ann Gyllenberg,

Epinephrine (adrenaline) absorption from new-generation, taste-masked sublingual tablets: A preclinical study Ousama Rachid, BPharm, MSc, Mutasem M.

The National Institutes of Allergy and Infectious Diseases networks on asthma in inner- city children: An approach to improved care William W. Busse,

Anaphylaxis Journal of Allergy and Clinical Immunology

Change in visual analog scale score in a pragmatic randomized cluster trial of allergic rhinitis Philippe-Jean Bousquet, MD, Christophe Combescure, PhD,

Objective monitoring of nasal patency and nasal physiology in rhinitis

An intranasal Syk-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment Eli O. Meltzer, MD, Robert B. Berkowitz,

Short course of systemic corticosteroids in sinonasal polyposis: A double-blind, randomized, placebo-controlled trial with evaluation of outcome measures

The Editors' Choice Journal of Allergy and Clinical Immunology

Frederikke K. Lomholt, BMSc, Sune F. Nielsen, PhD, Børge G

Asthma: The past, future, environment, and costs

Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal.

The correlation between allergic rhinitis and sleep disturbance

The effects of an H3 receptor antagonist (PF ) with fexofenadine on reducing allergic rhinitis symptoms Jeffrey R. Stokes, MD, Francisco A. Romero,

Lisa A. Beck, MD, Sarbjit Saini, MD

Advances in pediatric asthma in 2007

An intranasal Syk-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment Eli O. Meltzer, MD, Robert B. Berkowitz,

Natural history of cow’s milk allergy

Primary prevention of asthma and allergy

Presentation transcript:

Clinical outcomes and adverse effect monitoring in allergic rhinitis Elizabeth F. Juniper, MCSP, MSc, Elisabeth Ståhl, PhD, Richard L. Doty, MD, PhD, F. Estelle R. Simons, MD, FRCPC, David B. Allen, MD, Peter H. Howarth, BSc (Hons), DM, FRCP Journal of Allergy and Clinical Immunology Volume 115, Issue 3, Pages S390-S413 (March 2005) DOI: 10.1016/j.jaci.2004.12.014 Copyright © 2005 American Academy of Allergy, Asthma and Immunology Terms and Conditions

Fig 1 Improvement in RQLQ score with budesonide aqueous nasal spray (BANS) at 2 dose levels in comparison with placebo in perennial allergic rhinitis. NS, not significant. Adapted from Ståhl et al.13 Journal of Allergy and Clinical Immunology 2005 115, S390-S413DOI: (10.1016/j.jaci.2004.12.014) Copyright © 2005 American Academy of Allergy, Asthma and Immunology Terms and Conditions

Fig 2 Improvement in RQLQ score with fexofenadine compared with placebo and loratadine in seasonal allergic rhinitis. NS, not significant. Reproduced with permission from Blackwell Publishing.11 Journal of Allergy and Clinical Immunology 2005 115, S390-S413DOI: (10.1016/j.jaci.2004.12.014) Copyright © 2005 American Academy of Allergy, Asthma and Immunology Terms and Conditions

Fig 3 Improvement in individual QOL domains in seasonal allergic rhinitis with anti-IgE mAb therapy (omilizumab) in comparison with placebo. Adapted from Adelroth et al.37 Journal of Allergy and Clinical Immunology 2005 115, S390-S413DOI: (10.1016/j.jaci.2004.12.014) Copyright © 2005 American Academy of Allergy, Asthma and Immunology Terms and Conditions

Fig 4 UPSIT. This 40-odorant self-administered test consists of four 10-page booklets. Each page contains a different scratch-and-sniff scented strip and an associated multiple-choice question. Photo courtesy of Sensonics, Inc. © 2000 Sensonics, Inc. Journal of Allergy and Clinical Immunology 2005 115, S390-S413DOI: (10.1016/j.jaci.2004.12.014) Copyright © 2005 American Academy of Allergy, Asthma and Immunology Terms and Conditions

Fig 5 Change in olfactory test scores with the UPSIT according to sex and age. Journal of Allergy and Clinical Immunology 2005 115, S390-S413DOI: (10.1016/j.jaci.2004.12.014) Copyright © 2005 American Academy of Allergy, Asthma and Immunology Terms and Conditions

Fig 6 STT. Concentrations of PEA, ranging from 10−2 to 10−10 log vol/vol in half-log concentration steps, are provided, along with blanks for forced-choice testing. Photo courtesy of Sensonics, Inc. © 2000 Sensonics, Inc. Journal of Allergy and Clinical Immunology 2005 115, S390-S413DOI: (10.1016/j.jaci.2004.12.014) Copyright © 2005 American Academy of Allergy, Asthma and Immunology Terms and Conditions

Fig 7 Lack of effect of fexofenadine 360 mg administered at 3 times the standard clinical dose for allergic rhinitis on a range of objective outcome measures of CNS psychomotor function in comparison with placebo and an active control, promethazine 30 mg. Impairment was seen with the active control in 15 subjects in (A) total reaction time (TRT), (B) critical flicker fusion (CFF), (C) recognition reaction time (RRT), and (D) compensatory tracking task (CTT). ∗P < 0.05 versus placebo. +P < 0.05 versus fexofenadine. Reproduced with permission from Blackwell Publishing.126 Journal of Allergy and Clinical Immunology 2005 115, S390-S413DOI: (10.1016/j.jaci.2004.12.014) Copyright © 2005 American Academy of Allergy, Asthma and Immunology Terms and Conditions

Fig 8 Influence of age and therapy on crude rates per 10,000 for life-threatening ventricular arrhythmias and cardiac arrest within the population. ∗P < 0.05 versus terfenadine. OTC, over the counter. Reprinted with permission from Pratt et al. Excerpta Medica. © 1994.128 Journal of Allergy and Clinical Immunology 2005 115, S390-S413DOI: (10.1016/j.jaci.2004.12.014) Copyright © 2005 American Academy of Allergy, Asthma and Immunology Terms and Conditions

Fig 9 Change in height over 1 year in children treated with beclomethasone diproprionate 200 μg twice daily or placebo showing a significant reduction in growth in those receiving the intranasal steroid. Asterisks indicate time-points of significant difference between active and placebo therapy. BDP, beclomethasone dipropionate. Reproduced with permission from Pediatrics, Vol 105(2), page E23. © 2000 by the AAP.178 Journal of Allergy and Clinical Immunology 2005 115, S390-S413DOI: (10.1016/j.jaci.2004.12.014) Copyright © 2005 American Academy of Allergy, Asthma and Immunology Terms and Conditions

Fig 10 Change in height over 1 year in children treated with intranasal mometasone or placebo showing no deleterious effect of this intranasal steroid on growth. ∗P < 0.05 for increased growth in mometasone-treated children. MFNS, mometasone furoate nasal spray. Reproduced with permission from Pediatrics, Vol 105(2), page E22. © 2000 by the AAP.179 Journal of Allergy and Clinical Immunology 2005 115, S390-S413DOI: (10.1016/j.jaci.2004.12.014) Copyright © 2005 American Academy of Allergy, Asthma and Immunology Terms and Conditions